Clinical assessment of postoperative anemia associated with edoxaban in patients undergoing total knee arthroplasty compared to fondaparinux

Yasuhisa Izushi, Yoichiro Takami, Naofumi Shiota, Tomonori Tetsunaga, Yusuke Ookura, Kenichi Shimada, Takashi Egawa, Tsukasa Kiuchi, Toru Sato, Ritsugi Takuma

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Edoxaban, an oral direct factor Xa inhibitor, was developed and approved for anticoagulant thromboprophylaxis after total knee arthroplasty (TKA). We retrospectively investigated the postoperative anemia by oral administration of edoxaban 30 mg compared with fondaparinux 2.5 mg in TKA patients. Two hundred twenty nine patients who underwent TKA in National Hospital Organization Okayama Medical Center from July 2010 to June 2012 were divided into two groups; pre and post approval of edoxaban: fondaparinuxgroup (F-group) and edoxaban-group (E-group). As the primary endpoint, the frequency of postoperative anemia was evaluated. Blood coagulation values and relations between these parameters and postoperative anemia were also investigated. The frequency of postoperative anemia was significantly higher in E-group than F-group patients (52.7% vs. 37.8%; p

Original languageEnglish
Pages (from-to)516-523
Number of pages8
JournalBiological and Pharmaceutical Bulletin
Volume39
Issue number4
Publication statusPublished - Apr 1 2016

Keywords

  • Edoxaban
  • Postoperative Anemia
  • Prothrombin Time
  • Total Knee Arthroplasty

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Fingerprint Dive into the research topics of 'Clinical assessment of postoperative anemia associated with edoxaban in patients undergoing total knee arthroplasty compared to fondaparinux'. Together they form a unique fingerprint.

  • Cite this

    Izushi, Y., Takami, Y., Shiota, N., Tetsunaga, T., Ookura, Y., Shimada, K., Egawa, T., Kiuchi, T., Sato, T., & Takuma, R. (2016). Clinical assessment of postoperative anemia associated with edoxaban in patients undergoing total knee arthroplasty compared to fondaparinux. Biological and Pharmaceutical Bulletin, 39(4), 516-523.